References
- Paquet C, Hugon J. Could non-coding RNA be involved in Alzheimer’s disease? Med. Hypotheses69(2), 464–465 (2007).
- Xu P, Guo M, Hay BA. MicroRNAs and the regulation of cell death. Trends Genet.20(12), 617–624 (2004).
- Engels BM, Hutvagner G. Principles and effects of microRNA-mediated post-transcriptional gene regulation. Oncogene25, 6163–6169 (2006).
- Suen KC, Yu MS, So KF, Chang RC, Hugon J. Upstream signaling pathways leading to the activation of double-stranded-RNA-dependent serine/threonine protein kinase in β-amyloid peptide neurotoxicity J. Biol. Chem.278(50), 49819–49827 (2003).
- Nelson PT, Keller JN. RNA in brain disease: no longer “the messenger in the Middle”. J. Neuropathol. Exp. Neurol.66(6), 461–468 (2007).
- Lukiw W. Micro-RNA speciation in fetal, adult and Alzheimer’s disease hippocampus. Neuroreport18(3), 297–300 (2007).
- Wang WX, Rajeev BW, Stromberg AJ et al. The expression of miR-107 decreases early in Alzheimer’s disease and may accelerate disease progression through regulation of β-site amyloid precursor protein-cleaving enzyme 1. J. Neurosci.28(5), 1213–1223 (2008).
- Hebert S, Horr K, Nicolai L et al. Loss of microRNA mir-29a/b1 in sporadic Alzheimer’s disease correlates with increased BACE1/β secretase expression. Proc. Natl Acad. Sci. USA105(17), 6415–6420 (2008).
- Faghihi MA, Modarresi F, Khalil AM et al. Expression of noncoding RNA is elevated in Alzheimer’s disease and drives rapid feed-forward regulation of β secretase. Nat. Med.14(7), 723–730 (2008).
- Cogswell JP, Ward J, Taylor IA et al. Identification of miRNA changes in Alzheimer’s disease brain and CSF yields putative biomarkers and insights into disease pathways. J. Alz. Dis.14, 27–41 (2008).
- Krutzfeldt J, Rajewsky N, Braich R et al. Silencing of microRNAs in vivo with “antagomirs” Nature438, 685–689 (2005).
- Krutzfeldt J, Kuwajima S, Braich R et al. Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res.35(9), 2885–2892 (2007).